西藏药业
(600211)
| 流通市值：150.52亿 | | | 总市值：150.52亿 |
| 流通股本：3.22亿 | | | 总股本：3.22亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,650,705,155.36 | 712,108,915.5 | 2,806,713,295.85 | 2,175,443,351.59 |
| 营业收入 | 1,650,705,155.36 | 712,108,915.5 | 2,806,713,295.85 | 2,175,443,351.59 |
| 二、营业总成本 | 1,032,761,299.84 | 424,599,500.37 | 1,865,690,789 | 1,408,185,831.63 |
| 营业成本 | 89,115,752.32 | 37,344,055.65 | 162,296,561.26 | 110,341,212.94 |
| 税金及附加 | 21,804,929.77 | 7,061,159.67 | 37,095,519.04 | 30,435,075.08 |
| 销售费用 | 903,033,745.96 | 387,363,232.55 | 1,562,404,535.93 | 1,212,500,547 |
| 管理费用 | 52,433,245.59 | 26,174,144.96 | 122,137,403.61 | 79,711,039.37 |
| 研发费用 | 18,772,225.08 | 5,275,211.59 | 28,937,686.41 | 17,025,333.28 |
| 财务费用 | -52,398,598.88 | -38,618,304.05 | -47,180,917.25 | -41,827,376.04 |
| 其中:利息费用 | 136,257.56 | -1,854,082.29 | 9,291,711.67 | 9,216,592.02 |
| 其中:利息收入 | 50,569,771.93 | 35,816,485.82 | 59,273,510.36 | 50,652,199.96 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -821,339.67 | -1,423,805.47 | -18,985,201.5 | -4,032,722.33 |
| 加:投资收益 | 5,203,734.88 | 5,475,274.24 | 15,103,560.39 | 12,570,708.4 |
| 资产处置收益 | 69,267.28 | - | 1,960,495.62 | 2,082,461.73 |
| 资产减值损失(新) | -620,925.49 | - | 197,574.52 | -47,985.65 |
| 信用减值损失(新) | -769,395.66 | - | -633,689.04 | -362,337.02 |
| 其他收益 | 17,685,768.3 | 10,954,646.59 | 221,785,029.88 | 106,985,312.57 |
| 四、营业利润 | 638,690,965.16 | 302,515,530.49 | 1,160,450,276.72 | 884,452,957.66 |
| 加:营业外收入 | 190,948.7 | 120,324.49 | 361,232.67 | 789,520.01 |
| 减:营业外支出 | 1,561,480.32 | 988,416.37 | 8,727,448.95 | 2,416,036.5 |
| 五、利润总额 | 637,320,433.54 | 301,647,438.61 | 1,152,084,060.44 | 882,826,441.17 |
| 减:所得税费用 | 66,531,557.65 | 31,398,719.02 | 95,008,864.78 | 87,679,666.16 |
| 六、净利润 | 570,788,875.89 | 270,248,719.59 | 1,057,075,195.66 | 795,146,775.01 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 570,788,875.89 | 270,248,719.59 | 1,057,075,195.66 | 795,146,775.01 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 567,323,117.52 | 269,280,367.86 | 1,051,288,308.24 | 791,866,935.56 |
| 少数股东损益 | 3,465,758.37 | 968,351.73 | 5,786,887.42 | 3,279,839.45 |
| 扣除非经常损益后的净利润 | 542,843,268.89 | 253,408,358.35 | 858,700,122.54 | 686,505,609.1 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.76 | 0.84 | 3.26 | 2.46 |
| (二)稀释每股收益 | 1.76 | 0.84 | 3.26 | 2.46 |
| 八、其他综合收益 | -4,937,939.25 | -1,616,882.1 | 16,352,053.8 | -12,079,404.53 |
| 归属于母公司股东的其他综合收益 | -4,937,939.25 | -1,616,882.1 | 16,352,053.8 | -12,079,404.53 |
| 九、综合收益总额 | 565,850,936.64 | 268,631,837.49 | 1,073,427,249.46 | 783,073,875.81 |
| 归属于母公司股东的综合收益总额 | 562,385,178.27 | 267,663,485.76 | 1,067,640,362.04 | 779,787,531.03 |
| 归属于少数股东的综合收益总额 | 3,465,758.37 | 968,351.73 | 5,786,887.42 | 3,286,344.78 |
| 公告日期 | 2025-08-16 | 2025-04-29 | 2025-03-15 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |